HMG-CoA Reductase Inhibitor

This page covers all HMG-CoA Reductase Inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, HMG-CoA reductase.

Targets

3-hydroxy-3-methylglutaryl-coenzyme A reductase · HMG-CoA reductase

Marketed (4)

• Livalo · Kowa Co · Metabolic
• Mevacor · Merck & Co. · Metabolic
  Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.
• Lescol · Novartis · Metabolic
  Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol.
• Statins, HMG CoA · National Heart, Lung, and Blood Institute (NHLBI) · Cardiovascular
  Statins inhibit HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, thereby reducing LDL cholesterol levels.

Phase 3 pipeline (2)

• placebo + Rosuvastatin · Jeil Pharmaceutical Co., Ltd. · Cardiovascular
  Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.
• Statins with or without ezetimibe · Beijing Anzhen Hospital · Cardiovascular
  Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, while ezetimibe inhibits the absorption of cholesterol in the small intestine.

Phase 2 pipeline (1)

• BR5402A-1 · Boryung Pharmaceutical Co., Ltd · Cardiovascular
  BR5402A-1 is a small molecule that targets the HMG-CoA reductase enzyme.

Patent intelligence

• hmg coa reductase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates